Cutaneous T-Cell Lymphomas: A Review of New Discoveries and Treatments
- 7 February 2012
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 13 (1) , 102-121
Abstract
No abstract availableKeywords
This publication has 119 references indexed in Scilit:
- Inhibition of Glycogen Synthase Kinase-3 Increases the Cytotoxicity of EnzastaurinJournal of Investigative Dermatology, 2011
- Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviorsBlood, 2010
- Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell LymphomaClinical Cancer Research, 2010
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2009
- Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell MalignanciesJournal of Clinical Oncology, 2009
- Active Notch1 Confers a Transformed Phenotype to Primary Human MelanocytesCancer Research, 2009
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 casesBlood, 2009
- Psoralen plus ultraviolet A ± interferon-α treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-κB and T-cell receptor pathwaysBritish Journal of Dermatology, 2009
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006